VM1: Regulatory science – focus on biologicals

By Rhona Banks2021-11-23T13:45:00

Source: Adobe Stock

Opening the session, Ivo Claassen spoke about the unprecedented situation of the COVID-19 pandemic and the effects it has had on regulatory adaptation and emergency response preparedness. It was remarkable that novel mRNA vaccines for humans were developed and licensed in such a short period. He believes that there will be a considerable impact on the regulatory landscape in the long term.

How to read this journal article

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

REGISTER FOR FREE

1. Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

Create your own library to save your favourite content.
Sign up for Regulatory Rapporteur email newsletters.

Create a free account

Members login

2. Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.

JOIN TOPRA

3. TOPRA membership

Become a TOPRA member and join our global regulatory affairs community.

Great savings on our events and training.
Be part of our dynamic international community.
Contribute to the profession.
Grow your skills and knowledge.
Take your career to the next level.

Become a member